Syra Health Corp. SYRA

Syra Health partnered with HealthSync and was selected for the CMS ACCESS Model, advancing its long-term growth strategy. CMS ACCESS Model selection via HealthSync partnership signals significant strategic progress for Syra Health.

Syra Health Corp. achieved 23% revenue growth and raised gross margin to 44.5% during its second consecutive profitable quarter. Revenue growth and margin gains point to operational improvement that can lift near-term investor sentiment and valuation.

Syra Health appoints Dr. Cori McMahon as Chief Medical Officer to support its growth strategy. CMO hire adds leadership depth that can modestly influence operations and strategy execution.

Syra Health Corp. (SYRA) reported its first profitable quarter in Q1 2026, expanded margins, and strengthened its financial position. First profitable quarter with margin expansion and improved finances marks a significant positive shift for SYRA's trajectory and investor sentiment.

Syra Health Corp. (SYRA) won Innovation of the Year and the BioCrossroads Life Sciences Innovation Award at the 2026 TechPoint Mira Awards. Winning prominent innovation awards in life sciences boosts Syra Health's reputation and competitive positioning with moderate impact on market performance.

Syra Health and Nora Mental Health announce telehealth partnership to expand access to mental and behavioral health services across Indiana. Partnership expands telehealth into mental health in Indiana, moderately boosting SYRA's operations and market positioning.

Syra Health Corp. (SYRA) reported strong FY2025 results: 157% population health growth, 76% net loss reduction, targeting profitability by year-end 2026. Strong growth and massive loss reduction position SYRA for profitability, significantly boosting future performance and investor sentiment.

Syra Health Corp. (NASDAQ:SYRA) reported a net loss of US$3.76 million for the full year 2024, widening by 28% from FY 2023, with a loss per share of US$0.50 compared to US$0.60 in the previous year. Revenue increased by 45% to US$7.98 million. Shares have declined by 4.5% over the past week. The company has five warning signs, four of which are potentially serious. The widening net loss and warning signs indicate potential challenges that could moderately affect future performance.

Syra Health Corp. has appointed Gregory R. Alexander, a healthcare executive and former U.S. Marine, as its new Chief Executive Officer. This strategic move aims to drive growth within the company as it seeks to enhance its operations and market presence. The appointment of a seasoned executive is likely to significantly impact the company's strategic direction and growth potential.

Syra Health Corp. (SYRA) reported improved financial results for the third quarter, highlighting enhancements in margins and profitability metrics. The company demonstrated a positive trajectory in its financial performance, indicating effective operational strategies and potential for future growth. Improved margins and profitability metrics suggest significant positive shifts in financial performance and operational efficiency.

Syra Health Corp. (SYRA) is set to announce its financial results for the third quarter of 2025. The announcement is anticipated to provide insights into the company's performance and financial health during this period. The upcoming financial results may influence investor sentiment and provide insights into the company's operational performance.

Syra Health Corp. will participate in two upcoming healthcare conferences in Indiana, showcasing its commitment to advancing healthcare solutions and engaging with industry stakeholders. These events provide an opportunity for Syra Health to network, share insights, and potentially enhance its market presence. Participation in industry conferences can moderately enhance visibility and networking opportunities, impacting future business prospects.

Syra Health Corp. (SYRA) reported its second quarter financial results, highlighting progress towards profitability driven by margin gains and cost reductions. The company has implemented strategic measures to enhance operational efficiency, which contributed to improved financial metrics. Investors are encouraged by the positive trajectory as Syra Health continues to focus on sustainable growth. Significant improvements in margins and cost management are likely to enhance financial performance and investor sentiment.

Syra Health Corp. has secured a one-year contract valued at up to $2.1 million with a major insurance provider to supply medical management nurses. These nurses will assess medical needs, interpret benefits, and connect members to appropriate care. This agreement enhances Syra Health's existing services by adding direct care support to its data-driven offerings, aiming to improve health outcomes for insurance plan members. The contract significantly expands Syra Health's service offerings and direct impact on healthcare delivery, likely influencing its market position and financial performance.

Syra Health Corp. (OTCQB: SYRA) has achieved ISO 27001:2022 certification, emphasizing its commitment to data protection and security, particularly for its AI-backed mental health app, Syrenity. Interim CEO Priya Prasad stated that this certification reinforces the company's dedication to safeguarding personal information. The certification indicates that Syra Health has established a comprehensive framework for managing information security risks. Additionally, the company offers Syra Guardrails, a framework for the ethical use of AI in healthcare. The certification was granted by an independent auditor after a thorough assessment of the company's systems and policies. Achieving ISO 27001 certification significantly enhances Syra Health's credibility and competitive positioning in the healthcare technology sector.

Syra Health Corp. has been recommended for contract negotiations by the Indiana Department of Administration to implement the Child Mental Health Wraparound Access Site, valued at $5.8 million over three years. The company plans to subcontract 23.5% of the contract to Indiana-based firms. Revenue from this contract is expected to be recognized later this year. Dr. Deepika Vuppalanchi, interim CEO, emphasized Syra's integrated approach to delivering health solutions. This initiative aims to enhance care coordination and mental health outcomes for children in Indiana. The contract represents a significant strategic move that could enhance Syra Health's market position and financial performance.

Syra Health Corp. announced that its Board of Directors will initiate a national search for a new CEO to succeed Dr. Deepika Vuppalanchi, who will serve as interim CEO during the transition. This leadership change is part of a strategic succession plan aimed at driving growth in the healthcare sector. The Board is focused on finding a leader to enhance the Company's commitment to accessible and affordable healthcare solutions. Dr. Vuppalanchi, a co-founder, is expected to remain involved in the leadership team post-transition. The CEO search indicates a significant strategic shift that could impact the company's growth trajectory and market positioning.

Syra Health Corp. reported first quarter revenue of $1.9 million, reflecting a 6% increase year-over-year. The growth indicates a positive trend in the company's financial performance, suggesting effective strategies and potential for continued expansion in the healthcare sector. The revenue increase indicates moderate growth, which may positively influence financial performance but is not expected to drastically change the company's trajectory.

Syra Health Corp. announced its intention to voluntarily delist from the Nasdaq Capital Market due to non-compliance with the minimum bid price requirement. The company plans to file a Form 25 with the SEC around April 11, 2025, with the last trading day expected to be around April 21, 2025. This strategic decision aims to reduce costs and refocus on core operations. Following delisting, Syra Health's stock will be listed on the OTC market, although future trading is uncertain. Voluntary delisting from Nasdaq indicates significant strategic shifts that could impact financial health and investor sentiment.

Syra Health Corp. (NASDAQ: SYRA) announced a one-year, $660,000 extension of its Population Health contract with a national healthcare organization, bringing the total contract value to $1.32 million. Dr. Deepika Vuppalanchi, Chair and CEO, emphasized the trust partners place in Syra Health and the company's ability to deliver impactful healthcare solutions. The extension allows Syra Health to continue providing HEDIS® outreach and support services, contributing to improved healthcare quality and member outcomes. This contract supports the growth of Syra Health's Population Health business unit, which is key to diversifying revenue streams and enhancing long-term growth. The contract extension significantly enhances Syra Health's revenue and strengthens its position in the Population Health sector.

Syra Health Corp (SYRA) reported a 45% revenue increase in 2024, reaching $8 million, despite a decline in gross profit margin to 20.7%. Q4 2024 revenue was $2 million, with a net loss of $504,000, improved from $995,000 in Q4 2023. The company achieved significant growth in Population Health and Healthcare Workforce revenues but faced challenges with rising operating expenses and a total net loss of $3.7 million for the year. The Serenity app showed promising results, and new contracts were secured, enhancing revenue potential. However, compliance with NASDAQ listing standards remains a concern. Revenue growth and new contracts indicate potential for improved financial performance, but ongoing losses and margin pressures may limit overall impact.

Syra Health Corp. reported full-year revenue of $8.0 million for 2024, a 45% increase from $5.5 million in 2023. Population Health revenue surged 132% year-over-year, with Q4 2024 net losses nearly halved to $504,000. The company anticipates low double-digit revenue growth in 2025, driven by higher-margin business units. Operational efficiency improvements and new contracts, including significant agreements with government agencies, support sustainable growth. Management remains optimistic about profitability and product adoption, particularly for the mental health app Syrenity. Significant revenue growth and new contracts indicate a strong strategic position and potential for future profitability.

Syra Health Corp. has secured an extension of its population health contract in Shelby County, Tennessee, which will enhance its services and support healthcare initiatives in the region. This contract extension is expected to strengthen Syra Health's position in the market and improve its operational capabilities. The contract extension is a significant strategic move that could enhance Syra Health's market position and operational effectiveness.

Syra Health Corp. announced positive preliminary results from the Syrenity study led by Indiana University, which tested the efficacy of its mental health app. The study involved 135 participants with moderate to severe depression, showing trends toward reduced symptoms and improved overall well-being among app users. The app, which integrates psychology and technology, targets multiple mental health challenges. A second study will further analyze these results. Syra Health plans to publish the findings in a scientific journal, and the Syrenity app is available for download on major platforms. Positive preliminary results from a scientifically-backed mental health app could significantly enhance Syra Health's market position and investor sentiment.

Syra Health Corp. has secured a six-month, $135,000 contract with a Midwest university to develop virtual training modules in behavioral health. The training will equip professionals with skills to address behavioral health challenges. Additionally, Syra Health is implementing training for healthcare professionals in home and community-based settings, following a contract negotiation with Indiana's Division of Disability and Rehabilitative Services. The total value of combined training agreements is $4.9 million over four years, with options for renewals. The contracts represent significant strategic moves that could enhance Syra Health's market position and financial performance.

Syra Health Corp. wins new workforce contract and extends existing contract. The new contract wins and extension are expected to moderately influence the company's financial performance and competitive positioning.

Syra Health Corp. (SYRA) launches Syrenity, an evidence-based app for managing common mental health conditions. The launch of an evidence-based mental health app has the potential to significantly impact Syra Health Corp.'s future by expanding its product offerings and market reach.

Syra Health Corp. (SYRA) to present at NobleCon20 showcasing innovative healthcare solutions for mental health crisis, chronic conditions, and child welfare challenges. The presentation at NobleCon20 and the innovative healthcare solutions discussed are expected to significantly impact Syra Health Corp.'s future trajectory and market performance.

SYRA reported strong 3Q24 results with revenue up 42% to $2.3 million, driven by new contracts. Cost containment efforts led to margin improvement. Company optimistic about mental health app, Syrenity. The article highlights significant revenue growth, margin improvement, and new contract wins that are expected to have a major impact on SYRA's future performance.

Syra Health Corp. reported strong third quarter financial results with significant revenue growth and improved gross profit margins. The company highlighted strategic cost-cutting initiatives and progress towards profitability, including the successful launch of the Syrenity mental health app. The article describes significant financial improvements, strategic initiatives, and innovative product launches that are expected to have a major impact on Syra Health Corp.'s future performance.